More than two years after the COVID-19 pandemic began, people are realizing that the “new normal” will probably involve learning to co-exist with SARS-CoV-2 (the virus that causes COVID-19 disease). Some treatments are available, but with new variants emerging, researchers are looking toward new str
Scientists have discovered that apratoxin S4, an anticancer drug candidate that targets a human protein, can interfere with the replication of many viruses, including SARS-CoV-2 and influenza A, offering a possible pan-viral therapy.pandemic began, people are realizing that the “new normal” will probably involve learning to co-exist with. Some treatments are available, but with new variants emerging, researchers are looking toward new strategies.
Apratoxin S4 is effective against SARS-CoV-2 in human cells and could be a pan-viral therapeutic. Credit: Adapted from ACS Infectious Diseases 2022, DOI: 10.1021/acsinfecdis.2c00008